The majority of cancer drugs approved in Europe between 2009 and 2013 entered the market without clear evidence that they improved survival or quality of life for patients, finds a study published in BMJ. Study prompts calls to ‘raise the evidence bar’ for approval of new cancer drugs.
It may be far cheap to spend the money to enhance cancer patient’s spirit!
